Kim S H, Cho Y S, Choi Y J
Department of Ophthalmology, Kyungpook National University Hospital, Taegu, Korea.
Jpn J Ophthalmol. 1994;38(1):49-55.
A prospective study was performed to establish the effects on the bleeding time and the ocular toxicity of the use of intravitreal hemocoagulase (1 NIH thrombin unit/100 ml in BSS Plus) in patients undergoing vitrectomy. Sixty patients with diabetic retinopathy, penetrating ocular injury or non-diabetic retinal vascular disorder, in whom electroretinograms were recordable, were assigned to a study of Hemocoagulase-BSS Plus versus BSS Plus. The bleeding time was measured after cutting the proliferative attachments to the underlying retina. Intravitreal hemocoagulase significantly reduced the bleeding time, and this reduction of bleeding facilitated the surgery. A washout of hemocoagulase at the completion of the vitrectomy was not carried out. Hemocoagulase in the vitreous cavity assisted in maintaining hemostasis during the first week after diabetic vitrectomy. Postoperative electroretinography data did not show any disadvantage for the hemocoagulase infusate. Clinical study showed no adverse effect on the cornea, lens or visual acuity.
开展了一项前瞻性研究，以确定玻璃体腔内注射血凝酶（在平衡盐溶液（BSS Plus）中为1 NIH凝血酶单位/100 ml）对接受玻璃体切除术患者的出血时间及眼毒性的影响。将60例患有糖尿病性视网膜病变、穿透性眼外伤或非糖尿病性视网膜血管疾病且视网膜电图可记录的患者，纳入血凝酶-BSS Plus与BSS Plus的对比研究。在切断与视网膜下层的增殖性粘连后测量出血时间。玻璃体腔内注射血凝酶显著缩短了出血时间，而出血时间的缩短有利于手术操作。玻璃体切除术后未进行血凝酶的冲洗。玻璃体腔内的血凝酶有助于在糖尿病性玻璃体切除术后第一周维持止血。术后视网膜电图数据未显示血凝酶注入液有任何不利影响。临床研究表明，对角膜、晶状体或视力无不良影响。
